Jed J W Wiltzius is a prominent inventor based in Santa Monica, CA. He has made significant contributions to the field of biotechnology, particularly in the development of chimeric antigen receptors (CARs). With a total of 7 patents to his name, Wiltzius continues to push the boundaries of innovation in T cell therapy.

Latest Patents

Among his latest patents is the invention titled "Modified chimeric antigen receptors and methods of use." This patent discloses a chimeric antigen receptor (CAR) that includes a modified hinge, transmembrane, and/or intracellular domain. The invention also covers a polynucleotide encoding a CAR that comprises a costimulatory domain. Additionally, it discusses the use of cells containing the CAR in T cell therapy. Another notable patent is "Chimeric polypeptides and uses thereof," which provides novel peptides and polypeptide compositions, including linkers and fusion proteins. These peptides are designed to facilitate proper folding and reduce immunogenicity, enhancing the effectiveness of antigen binding molecules.

Career Highlights

Jed J W Wiltzius is currently associated with Kite Pharma, Inc., a leading company in the field of cell therapy. His work at Kite Pharma focuses on advancing innovative therapies that harness the power of the immune system to fight cancer. His expertise and contributions have positioned him as a key figure in the biotechnology sector.

Collaborations

Wiltzius collaborates with various professionals in the field, including his coworker Stuart A Sievers. Together, they work on groundbreaking projects that aim to improve therapeutic outcomes for patients.

Conclusion

Jed J W Wiltzius exemplifies the spirit of innovation in biotechnology through his patents and contributions to T cell therapy. His work continues to inspire advancements in the field, making a significant impact on cancer treatment.

Profile summary based on public USPTO records.